Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MF59-adjuvanted H5N1 influenza vaccine in adults
NCT00382187Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2006
- Primary completion
- Jan 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Audenz in avian influenza (HPAI) (3 arms), sponsored by Novartis. Primary endpoints: Seroprotection rate at day 43, Geometric Mean Titers at day 43 and 1 more. Started Nov 2006; status: completed.
02
Drugs
Audenz
03
Conditions
avian influenza (HPAI)
Beyond the preview
Go deeper on NCT00382187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00382187.